Inventor · disambiguated record
Purakkattle Biju
Also filed as: BIJU PURAKKATTLE · BIJU PURAKKATTLE J · BIJU PURAKKATTLE JOHNY
26 granted patents·6 pending applications·170 citations·filing 2002–2017
95Inventor score
Files withSCHERING CORP14MERCK SHARP & DOHME9PHARMACOPEIA DRUG DISCOVERY2ANTHES JOHN C1ASLANIAN ROBERT G1
Top patents by PatentIndex Score
32 records- 0194US7132445B23,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligandsPHARMACOPEIA DRUG DISCOVERY·Filed 2003·Granted Nov 7, 2006·58 cites·82 claims
- 0290US7638531B2Phenoxypiperidines and analogs thereof useful as histamine H3 antagonistsSCHERING CORP·Filed 2006·Granted Dec 29, 2009·19 cites·18 claims
- 0388US7964646B23,4-DI-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligandsSCHERING CORP·Filed 2006·Granted Jun 21, 2011·10 cites·47 claims
- 0488US7947720B23,4-di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligandsSCHERING CORP·Filed 2009·Granted May 24, 2011·10 cites·4 claims
- 0585US9932311B2Antidiabetic tricyclic compoundsMERCK SHARP & DOHME·Filed 2014·Granted Apr 3, 2018·4 cites·24 claims
- 0684US8524697B2C20-C21 substituted glucocorticoid receptor agonistsANTHES JOHN C·Filed 2008·Granted Sep 3, 2013·20 cites·7 claims
- 0783US7718678B2Di-substituted oxadiazoles as CXC-chemokine receptor ligandsSCHERING CORP·Filed 2006·Granted May 18, 2010·7 cites·42 claims
- 0879US7960433B2Treatment of chemokine mediated diseasesSCHERING CORP·Filed 2007·Granted Jun 14, 2011·4 cites·11 claims
- 0978US9527875B2Antidiabetic tricyclic compoundsMERCK SHARP & DOHME·Filed 2013·Granted Dec 27, 2016·4 cites·13 claims
- 1078US8927559B2Quinazolinone-type compounds as CRTH2 antagonistsASLANIAN ROBERT G·Filed 2011·Granted Jan 6, 2015·6 cites·16 claims
- 1178US8592383B2Cycloalkyl-fused tetrahydroquinolines as CRTH2 receptor modulatorsHUANG XIANHAI·Filed 2012·Granted Nov 26, 2013·5 cites·48 claims
- 1278US7691856B2Thiadiazoledioxides and thiadiazoleoxides as CXC- and CC-chemokine receptor ligandsSCHERING CORP·Filed 2007·Granted Apr 6, 2010·3 cites·67 claims
- 1377US10138212B2Aminoquinazoline compounds as A2A antagonistMERCK SHARP & DOHME·Filed 2016·Granted Nov 27, 2018·2 cites·18 claims
- 1477US9834563B2Antidiabetic substituted heteroaryl compoundsMERCK SHARP & DOHME·Filed 2014·Granted Dec 5, 2017·4 cites·13 claims
- 1572US9469615B2Quinoxalines and AZA-quinoxalines as CRTH2 receptor modulatorsBOYCE CHRISTOPHER W·Filed 2011·Granted Oct 18, 2016·4 cites·27 claims
- 1672US7985748B2ALPHA2C adrenoreceptor agonistsPHARMACOPEIA DRUG DISCOVERY·Filed 2010·Granted Jul 26, 2011·2 cites·15 claims
- 1770US7338968B2Thiadiazoles AS CXC- and CC- chemokine receptor ligandsSCHERING CORP·Filed 2004·Granted Mar 4, 2008·4 cites·46 claims
- 1869US7671212B2Isothiazole dioxides as CXC- and CC-chemokine receptor ligandsSCHERING CORP·Filed 2004·Granted Mar 2, 2010·4 cites·39 claims
- 1956US7786149B2Thiadiazoles as CXC- and CC- chemokine receptor ligandsSCHERING CORP·Filed 2007·Granted Aug 31, 2010·0 cites·19 claims
- 2053US2011213029A13,4-Di-Substituted Cyclobutene-1,2-Diones as CXC-Chemokine Receptor LigandsSCHERING CORP·Filed 2011·Application pending·0 cites
- 2152US2004106794A13,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligandsSCHERING CORP·Filed 2002·Application pending·0 cites
- 2251US2007093477A1Alpha2C adrenoreceptor agonistsSCHERING CORP AND PHARMACOPEIA·Filed 2006·Application pending·0 cites
- 2349US2004186142A1Thiadiazoledioxides and thiadiazoleoxides as CXC- and CC- chemokine receptor ligandsSCHERING CORP PHARMACOPEIA INC·Filed 2003·Application pending·0 cites
- 2447US7897606B25,6-di-substituted oxadiazolopyrazines and thiadiazolopyrazines as CXC-chemokine receptor ligandsSCHERING CORP·Filed 2006·Granted Mar 1, 2011·0 cites·12 claims
- 2547US2004053953A1Treatment of chemokine mediated diseasesSCHERING CORP·Filed 2003·Application pending·0 cites
- 2647US2011262368A1C21 thioethers as glucocorticoid receptor agonistsSCHERING CORP·Filed 2008·Application pending·0 cites
- 2746US10519115B2Antidiabetic tricyclic compoundsMERCK SHARP & DOHME·Filed 2014·Granted Dec 31, 2019·0 cites·21 claims
- 2842US10988487B2Substituted n′-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase (IDO) inhibitorsMERCK SHARP & DOHME·Filed 2017·Granted Apr 27, 2021·0 cites·20 claims
- 2942US10399972B2Tricyclic compounds as inhibitors of mutant IDH enzymesMERCK SHARP & DOHME·Filed 2016·Granted Sep 3, 2019·0 cites·19 claims
- 3039US10538497B2Compounds as indoleamine 2,3-dioxygenase inhibitorsMERCK SHARP & DOHME·Filed 2016·Granted Jan 21, 2020·0 cites·19 claims
- 3134US10442819B2Tricyclic compounds as inhibitors of mutant IDH enzymesFISCHER CHRISTIAN·Filed 2015·Granted Oct 15, 2019·0 cites·16 claims
- 3234US10000454B2Antidiabetic tricyclic compoundsMERCK SHARP & DOHME·Filed 2015·Granted Jun 19, 2018·0 cites·22 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →